The potential of carbonic anhydrase enzymes as a novel target for anti-cancer treatment

被引:6
|
作者
Zhou, Xiao-qun [1 ,2 ]
Ma, Xian-li [3 ]
Ariffin, Nur Syamimi [1 ]
机构
[1] Univ Teknol MARA, Fac Pharm, Dept Pharmacol & Pharmaceut Chem, Bandar Puncak Alam 42300, Selangor, Malaysia
[2] Guilin Med Univ, Guilin, Peoples R China
[3] Guangxi Univ, Nanning, Peoples R China
关键词
Carbonic anhydrase; Carbon dioxide; Bicarbonate; pH; Homeostasis; Anti-cancer; TRANSMEMBRANE ISOZYME-XIV; CRYSTAL-STRUCTURE; SELECTIVE INHIBITORS; ISOFORMS IX; EXTRACELLULAR DOMAIN; NATURAL-PRODUCTS; CA-XIII; EXPRESSION; COUMARINS; LOCALIZATION;
D O I
10.1016/j.ejphar.2024.176677
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Carbonic anhydrase (CA) is a zinc-dependent metal enzyme that maintains the pH and carbon dioxide (CO2) homeostasis in cells by catalyzing the reversible hydration and dehydration of CO2 and bicarbonate (HCO3-). In mammals, there are 16 isozymes of CA existed, namely CAI to CAXIV, but only 15 isozymes are found in humans except CAXV. Human CAs have highly conserved catalytic domains, all of which are distributed in different tissues and play important physiological roles. Changes in their functions may disrupt the typical distribution of CAs throughout human body and therefore CAs can be used as diagnostic biomarkers for many diseases. Furthermore, the expression of CAs is correlated to the progression of numerous tumors, therapeutic sensitivity and patient prognosis. In this review, we discuss thoroughly the structure of CAs, their functional activities in human physiology, dysregulations and diseases related to CAs, and different types of CA inhibitors that can reverse their dysregulation.
引用
收藏
页数:16
相关论文
共 50 条
  • [41] ACQUISITION AND DEVELOPMENT OF NOVEL COMPOUNDS AS POTENTIAL ANTI-CANCER AGENTS
    NARAYANAN, VL
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1979, (SEP): : 9 - 9
  • [42] NHE-1: A Promising Target for Novel Anti-cancer Therapeutics
    Loo, Ser Yue
    Chang, Michelle Ker Xing
    Chua, Charis Sui Huay
    Kumar, Alan Prem
    Pervaiz, Shazib
    Clement, Marie Veronique
    CURRENT PHARMACEUTICAL DESIGN, 2012, 18 (10) : 1372 - 1382
  • [43] Novel heterocyclic NO-donors as potential anti-cancer agents
    Richardson, Monica
    Robinson, Elizabeth
    Turner, Christopher
    Allin, Steve
    Richardson, Alan
    Pearson, Russell
    NITRIC OXIDE-BIOLOGY AND CHEMISTRY, 2012, 27 : S37 - S37
  • [44] Anti-cancer activity and potential mechanism of a novel aspirin derivative
    Zong, Ming
    Fan, Dan-Dan
    Lin, Shan
    Song, Yan-Ping
    Wang, Ze-Yu
    Ma, Xiao-Liang
    Qiu, Wei-Hua
    Bai, Yu-Hua
    Li, Lei
    Li, Sen
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2016, 791 : 137 - 146
  • [45] Computational Studies on Isolated Compounds of Sclerochloa dura; their Efficacy towards Carbonic Anhydrase Inhibition and Anti-cancer Drug Targets
    Ali, Majid
    Zaidi, Asma
    Farooq, Umar
    Sarwar, Rizwana
    Bukhari, Syed Majid
    LETTERS IN DRUG DESIGN & DISCOVERY, 2021, 18 (12) : 1107 - 1116
  • [46] FLIP as an anti-cancer therapeutic target
    Yang, Jin Kuk
    YONSEI MEDICAL JOURNAL, 2008, 49 (01) : 19 - 27
  • [47] MCM2 and Carbonic Anhydrase 9 Are Novel Potential Targets for Neuroblastoma Pharmacological Treatment
    Garbati, Patrizia
    Barbieri, Raffaella
    Cangelosi, Davide
    Zanon, Carlo
    Costa, Delfina
    Eva, Alessandra
    Thellung, Stefano
    Calderoni, Matilde
    Baldini, Francesca
    Tonini, Gian Paolo
    Modesto, Paola
    Florio, Tullio
    Pagano, Aldo
    BIOMEDICINES, 2020, 8 (11) : 1 - 19
  • [48] Isatin analogs as novel inhibitors of Candida spp. β-carbonic anhydrase enzymes
    Akdemir, Atilla
    Guzel-Akdemir, Ozlen
    Karali, Nilgun
    Supuran, Claudiu T.
    BIOORGANIC & MEDICINAL CHEMISTRY, 2016, 24 (08) : 1648 - 1652
  • [49] MEk as a target for anti-cancer therapy
    LoRusso, PM
    ANNALS OF ONCOLOGY, 2006, 17 : 24 - 24
  • [50] Aurora kinases as an anti-cancer target
    Ikezoe, Takayuki
    CANCER LETTERS, 2008, 262 (01) : 1 - 9